<DOC>
	<DOCNO>NCT00397358</DOCNO>
	<brief_summary>This Phase IV study evaluate triglyceride level peritoneal dialysis patient .</brief_summary>
	<brief_title>Effect Extraneal ( Icodextrin ) Triglyceride Levels PD Patients</brief_title>
	<detailed_description>This prospective , open label , multi-center study evaluate use 7.5 % icodextrin use long-dwell exchange peritoneal dialysis patient elevate triglyceride level . Fasting triglyceride level measure study .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Icodextrin</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<criteria>write informed consent CAPD/APD dialysis least 3 month Elevated fast triglyceride level enrol another study require IRB approval allergy starchbased polymer glycogen storage disease maltose isomaltose intolerance active alcohol/substance abuse Pregnant nursing receive investigational drug within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Peritoneal Dialysis</keyword>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>Extraneal ( 7.5 % icodextrin ) Peritoneal Dialysis Solution</keyword>
</DOC>